The association of hematological indices with the response to cardiac resynchronization therapy: a single-center study.
Cardiac resynchronization therapy
heart failure
hematological indices
predictors
responders
Journal
Hippokratia
ISSN: 1108-4189
Titre abrégé: Hippokratia
Pays: Greece
ID NLM: 101296613
Informations de publication
Date de publication:
Historique:
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
ppublish
Résumé
Cardiac resynchronization therapy (CRT) is an established therapeutic option for patients with heart failure (HF) and left ventricular ejection fraction (LVEF) ≤35 % who meet specific criteria according to current guidelines. However, up to 40 % of patients have no response to CRT. Our study aimed to investigate the association between different hematological and biochemical indices and response to CRT. Patients with HF due to ischemic or dilated cardiomyopathy referred to our hospital for CRT implantation from January 2013 to November 2017 were included in the study. Response to CRT was defined as an increase in LVEF ≥10 % or a decrease in left ventricular end-systolic volume (LVESV) ≥15 % at six months of follow-up. A total of 48 patients (mean age: 66.2 ± 9.5 years, 81.3 % males) were included in the study. Of these HF patients, 29 (60.4 %) had ischemic cardiomyopathy, and 19 (39.6 %) had dilated cardiomyopathy. At six months of follow-up, 37 patients (77.1 %) had responded to CRT. Ten patients (20.8 %) had ventricular tachycardia (VT), 24 (50 %) patients were hospitalized, and two patients (4.2 %) died during the follow-up period. Multivariate analysis demonstrated that age (p =0.03) and creatinine levels (p =0.02) were independent predictors of the response to CRT. No significant associations between hematological markers (white blood cells, neutrophils, lymphocytes, platelets, neutrophil to lymphocyte ratio, red blood cells distribution width) and CRT response were observed. A smaller increase in LVEF and a smaller decrease in LVESV were predictive for VT occurrence and hospitalizations in patients receiving CRT. No significant association between hematological markers and response to CRT was found. HIPPOKRATIA 2019, 23(3): 118-125.
Sections du résumé
BACKGROUND
BACKGROUND
Cardiac resynchronization therapy (CRT) is an established therapeutic option for patients with heart failure (HF) and left ventricular ejection fraction (LVEF) ≤35 % who meet specific criteria according to current guidelines. However, up to 40 % of patients have no response to CRT. Our study aimed to investigate the association between different hematological and biochemical indices and response to CRT.
METHODS
METHODS
Patients with HF due to ischemic or dilated cardiomyopathy referred to our hospital for CRT implantation from January 2013 to November 2017 were included in the study. Response to CRT was defined as an increase in LVEF ≥10 % or a decrease in left ventricular end-systolic volume (LVESV) ≥15 % at six months of follow-up.
RESULTS
RESULTS
A total of 48 patients (mean age: 66.2 ± 9.5 years, 81.3 % males) were included in the study. Of these HF patients, 29 (60.4 %) had ischemic cardiomyopathy, and 19 (39.6 %) had dilated cardiomyopathy. At six months of follow-up, 37 patients (77.1 %) had responded to CRT. Ten patients (20.8 %) had ventricular tachycardia (VT), 24 (50 %) patients were hospitalized, and two patients (4.2 %) died during the follow-up period. Multivariate analysis demonstrated that age (p =0.03) and creatinine levels (p =0.02) were independent predictors of the response to CRT. No significant associations between hematological markers (white blood cells, neutrophils, lymphocytes, platelets, neutrophil to lymphocyte ratio, red blood cells distribution width) and CRT response were observed.
CONCLUSIONS
CONCLUSIONS
A smaller increase in LVEF and a smaller decrease in LVESV were predictive for VT occurrence and hospitalizations in patients receiving CRT. No significant association between hematological markers and response to CRT was found. HIPPOKRATIA 2019, 23(3): 118-125.
Types de publication
Journal Article
Langues
eng
Pagination
118-125Informations de copyright
Copyright 2019, Hippokratio General Hospital of Thessaloniki.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest regarding this manuscript.
Références
Heart Rhythm. 2010 Dec;7(12):1777-82
pubmed: 20833266
J Interv Card Electrophysiol. 2018 Apr;51(3):237-244
pubmed: 29460235
Przegl Lek. 2009;66(3):130-3
pubmed: 19689037
Eur Heart J. 2009 Apr;30(7):782-8
pubmed: 19168870
J Interv Card Electrophysiol. 2015 Dec;44(3):297-304
pubmed: 26453528
J Cardiovasc Electrophysiol. 2014 Nov;25(11):1188-95
pubmed: 24891182
Eur Heart J. 2013 Aug;34(29):2281-329
pubmed: 23801822
Int Heart J. 2012;53(5):306-12
pubmed: 23038092
Scand Cardiovasc J. 2010 Dec;44(6):337-45
pubmed: 21080864
J Card Fail. 2008 Sep;14(7):539-46
pubmed: 18722318
J Card Fail. 2010 Mar;16(3):230-8
pubmed: 20206898
Pacing Clin Electrophysiol. 2015 Oct;38(10):1192-200
pubmed: 26179289
N Engl J Med. 2005 Apr 14;352(15):1539-49
pubmed: 15753115
PLoS One. 2012;7(11):e48926
pubmed: 23152822
Curr Opin Cardiol. 2015 Jan;30(1):40-9
pubmed: 25469590
J Arrhythm. 2017 Oct;33(5):417-423
pubmed: 29021843
Kardiol Pol. 2016;74(2):119-26
pubmed: 26202536
Int J Cardiol. 2017 Sep 15;243:347-353
pubmed: 28600101
Congest Heart Fail. 2012 Mar-Apr;18(2):79-84
pubmed: 22432553
Med Sci Monit. 2013 May 17;19:373-7
pubmed: 23686301
J Interv Card Electrophysiol. 2012 Nov;35(2):215-8
pubmed: 22688952
J Am Coll Cardiol. 2003 Oct 15;42(8):1454-9
pubmed: 14563591
Eur Heart J. 2011 Jul;32(13):1622-30
pubmed: 21075774
N Engl J Med. 2004 May 20;350(21):2140-50
pubmed: 15152059
J Am Coll Cardiol. 2013 Jan 22;61(3):e6-75
pubmed: 23265327
Circulation. 2009 Nov 10;120(19):1858-65
pubmed: 19858419
J Am Coll Cardiol. 2011 Feb 1;57(5):549-55
pubmed: 21272745
Circulation. 2006 Jan 17;113(2):266-72
pubmed: 16401777
J Am Coll Cardiol. 2011 Nov 22;58(22):2282-9
pubmed: 22093504
J Card Fail. 2006 Jun;12(5):353-9
pubmed: 16762798
Heart. 2004 Nov;90(11):1263-8
pubmed: 15486117